Cellectis S.A.
NASDAQ:CLLSBiotechnology
Healthcare
$1.06 -0.65%
-$0.02 today
- Market cap
- $106.78M
- Beta
- 2.75
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.67
52W Low $1.35High $5.48
Volume 0.02M
Average 0.04M
Income Statement
Follow revenue through to earnings.
Revenue
$72.95M
FY 2025 · Annual
+75.8% YoYOperating Income
-$33.08M
FY 2025 · Annual
Net Income
-$67.59M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 30.35M | 19.17M | 755K | 41.51M | 72.95M |
| Cost of Revenue | 1.84M | 8.48M | 7.42M | 9.18M | 9.8M |
| Gross Profit | 28.5M | 10.69M | (6.66M) | 32.32M | 63.15M |
| Gross Margin | 93.9% | 55.7% | -882.6% | 77.9% | 86.6% |
| Research & Development | 117.84M | 97.5M | 87.65M | 90.54M | 93.52M |
| Selling, General & Admin | 22.88M | 8.9M | 8.12M | 8.42M | 8.6M |
| Operating Expenses | 131.98M | 100.35M | 90.64M | 91.88M | 96.23M |
| Depreciation & Amortization | 14.16M | 18.44M | 18.52M | 19.85M | 20.06M |
| EBITDA | (78.43M) | (76.38M) | (92.64M) | (9.46M) | (39.85M) |
| EBITDA Margin | -258.4% | -398.4% | -12269.8% | -22.8% | -54.6% |
| Operating Income | (103.48M) | (89.67M) | (97.3M) | (59.55M) | (33.08M) |
| Operating Margin | -341.0% | -467.7% | -12887.7% | -143.5% | -45.3% |
| Interest Income | 719K | 1.12M | 3.61M | 11.28M | 9.5M |
| Interest Expense | 4.37M | 3.79M | 5.31M | 7.45M | 8.11M |
| Other Income / Expenses | 6.73M | (8.94M) | (19.16M) | 22.79M | (34.94M) |
| Income Before Tax | (96.75M) | (98.6M) | (116.46M) | (36.76M) | (68.02M) |
| Pre-Tax Margin | -318.8% | -514.3% | -15425.7% | -88.6% | -93.2% |
| Income Tax Expense | (3K) | 87K | 371K | 0 | (423K) |
| Net Income | (114.2M) | (106.14M) | (101.06M) | (36.76M) | (67.59M) |
| Net Margin | -376.3% | -553.6% | -13385.3% | -88.6% | -92.7% |
| EPS (Basic) | (1.93) | (2.33) | (1.77) | (0.41) | (0.68) |
| EPS (Diluted) | (1.93) | (2.33) | (1.77) | (0.41) | (0.68) |
| 44.82M | 45.55M | 57.01M | 90.57M | 100.28M | |
| 44.82M | 45.55M | 57.01M | 90.57M | 100.28M |
CLLS Earnings Waterfall · TTM
NASDAQ:CLLS · Revenue to Net Income
Key Ratios
EPS$-0.68
Gross Margin67.9%
Net Margin-175.2%
P/E Ratio27.7
P/S Ratio29.7
Analysis
$68.1M of revenue converted into -$67.3M of net income for the selected period. Gross margin is 67.9% and net margin is -175.2%, showing how much revenue survives after costs and taxes. EPS is $-0.68, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 13, 2026 | |
| 6-K | 6-K filing | Nov 12, 2026 | |
| SC 13D/A | SC 13D/A filing | Nov 9, 2026 | |
| 6-K | 6-K filing | Nov 9, 2026 | |
| 6-K | 6-K filing | Oct 28, 2026 |
How much revenue does CLLS generate?
Cellectis S.A. (CLLS) reported $72.95M of revenue in fiscal 2025.
Is CLLS profitable?
Cellectis S.A. (CLLS) reported -$67.59M of net income, with a net margin of -92.7%.
Continue the stock analysis
Jump to another research area for this company.